GP
GNCA

GLG Partners’s Genocea Biosciences, Inc. GNCA Stock Holding History

GLG Partners’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,920
Closed -$94K – 486
2017
Q1 		$94K Buy
+1,920
New +$75K ﹤0.01% 423

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GLG Partners's GNCA Position: Q2 2017 in Review

GLG Partners sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2017, closing a stake of 1,920 shares — an estimated $94K sold.

GLG Partners first reported a position in GNCA in Q1 2017 and held it in 1 quarter. The position peaked at $94K in Q1 2017. 61 funds tracked by Wall St. Rank hold GNCA as of Q2 2017.

  • GLG Partners reported no remaining Genocea Biosciences, Inc. position as of Q2 2017 after selling out during the quarter.
  • GLG Partners sold 1,920 Genocea Biosciences, Inc. shares in Q2 2017, an estimated $94K.
  • GLG Partners first reported a position in Genocea Biosciences, Inc. in Q1 2017 and held it in 1 quarter.
  • GLG Partners's Genocea Biosciences, Inc. position peaked at $94K in Q1 2017.
  • 61 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.